From Nuclear Winter to Renewal: Biotech Investing for 2026

In this episode of Denatured, Jennifer C. Smith-Parker speaks to Maha Katabi, general partner at Sofinnova Investments and Andrew Lam, managing director, head of Biotech Private Equity at Ally Bridge Group, about how M &A dynamics, dealmaking and global partnerships are reshaping portfolio valuations and paths to growth in 2026. HostJennifer Smith-Parker, Director of Insights, BioSpaceGuestsMaha Katabi, General Partner, Sofinnova InvestmentsAndrew Lam, Managing Director, Head of Biotech Private Equity, Ally Bridge Group (ABG)Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.